Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.
2.

3-aminobenzamide prevents restraint-evoked immunocompromise.

Neigh GN, Samuelsson AR, Bowers SL, Nelson RJ.

Brain Behav Immun. 2005 Jul;19(4):351-6. Epub 2005 Jan 11.

PMID:
15944075
3.
4.

Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis.

Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, Boulares AH, Smulson ME.

J Biol Chem. 1998 May 29;273(22):13703-12.

6.
7.

Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers.

Shieh WM, Amé JC, Wilson MV, Wang ZQ, Koh DW, Jacobson MK, Jacobson EL.

J Biol Chem. 1998 Nov 13;273(46):30069-72.

8.

Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia.

Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, Pieper A, Wang ZQ, Dawson TM, Snyder SH, Dawson VL.

Nat Med. 1997 Oct;3(10):1089-95.

PMID:
9334719
9.

Roles of DNA fragmentation factor and poly(ADP-ribose) polymerase in an amplification phase of tumor necrosis factor-induced apoptosis.

Boulares AH, Zoltoski AJ, Yakovlev A, Xu M, Smulson ME.

J Biol Chem. 2001 Oct 12;276(41):38185-92. Epub 2001 Jul 18.

10.

Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia.

Xu Z, Zhang J, David KK, Yang ZJ, Li X, Dawson TM, Dawson VL, Koehler RC.

Am J Physiol Regul Integr Comp Physiol. 2010 Jul;299(1):R215-21. doi: 10.1152/ajpregu.00747.2009. Epub 2010 Apr 28.

11.

Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia.

Suh SW, Aoyama K, Chen Y, Garnier P, Matsumori Y, Gum E, Liu J, Swanson RA.

J Neurosci. 2003 Nov 19;23(33):10681-90.

12.

Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

Shall S, de Murcia G.

Mutat Res. 2000 Jun 30;460(1):1-15. Review.

PMID:
10856830
13.

Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction.

Szántó M, Rutkai I, Hegedus C, Czikora Á, Rózsahegyi M, Kiss B, Virág L, Gergely P, Tóth A, Bai P.

Cardiovasc Res. 2011 Dec 1;92(3):430-8. doi: 10.1093/cvr/cvr246. Epub 2011 Sep 15.

PMID:
21921080
14.

Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure.

Pillai JB, Russell HM, Raman J, Jeevanandam V, Gupta MP.

Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H486-96. Epub 2004 Sep 16.

15.

Poly (ADP-ribose) transferase/polymerase-1-deficient mice resistant to age-dependent decrease in β-cell proliferation.

Gong L, Liu FQ, Wang Y, Hou XG, Zhang W, Qin WD, Zhang Y, Chen L, Zhang MX.

Mol Med. 2012 Jul 18;18:816-24. doi: 10.2119/molmed.2011.00458.

16.

Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis.

D'Amours D, Sallmann FR, Dixit VM, Poirier GG.

J Cell Sci. 2001 Oct;114(Pt 20):3771-8.

17.
18.

Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts.

Andreone TL, O'Connor M, Denenberg A, Hake PW, Zingarelli B.

J Immunol. 2003 Feb 15;170(4):2113-20.

19.

Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition.

Alano CC, Ying W, Swanson RA.

J Biol Chem. 2004 Apr 30;279(18):18895-902. Epub 2004 Feb 11.

20.

Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.

Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Haskó G, Szabó C.

J Pharmacol Exp Ther. 2002 Mar;300(3):862-7.

Supplemental Content

Support Center